Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | CA1 | P00915 | 11/20 | 0.75 |
| ▸ | CA2 | P00918 | 11/20 | 0.75 |
| ▸ | CA9 | Q16790 | 6/20 | 0.75 |
| ▸ | CA12 | O43570 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.67 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | CA4 | P22748 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14372393 | 0.91 | MEN1 (0.72) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL14161532 | 0.91 | MEN1 (0.71) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL14372347 | 0.90 | MEN1 (0.71) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL14372332 | 0.88 | CA1 (0.65) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL14372362 | 0.87 | CA1 (0.77) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL14372369 | 0.87 | CA1 (0.76) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL14372342 | 0.87 | CA1 (0.71) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL14372344 | 0.87 | MEN1 (1.00) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL14372490 | 0.86 | KCNK3 (0.69) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL14372371 | 0.85 | MEN1 (0.65) | MEN1KMT2ACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117858875-A | Hydroxy-and (halo) alkoxy-substituted tetrahydrofurans as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-21 | — | — | US | disclosed |
| CN-107001283-B | FLT3 receptor antagonists | 国家健康与医学研究院 | 2021-05-25 | — | — | CN | disclosed |
| EP-3174859-B1 | FLT3 RECEPTOR ANTAGONISTS | INST NAT SANTE RECH MED (FR) | 2020-04-29 | — | — | EP | disclosed |
| CN-105683157-B | Sulfonamides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2019-07-19 | — | — | CN | disclosed |
| US-10239830-B2 | Benzenesulfonamide upregulators of NPC1 for Neimann-Pick disease and other lysosomal storage disorders | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239830-B2 | Benzenesulfonamide upregulators of NPC1 for Neimann-Pick disease and other lysosomal storage disorders | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-03-26 | — | — | US | disclosed |
| US-10065937-B2 | FLT3 receptor antagonists | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-04 | — | — | US | disclosed |
| CN-108395452-A | The prodrug of pyridine keto-amide as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2018-08-14 | — | — | CN | disclosed |
| CN-105814067-B | Prodrugs of pyridone amides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2018-05-18 | — | — | CN | disclosed |
| EP-3256116-A1 | BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS | Icahn School of Medicine at Mount Sinai (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3256116-A1 | BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS | Icahn School of Medicine at Mount Sinai (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-08-17 | — | — | US | disclosed |
| EP-3174859-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016130774-A1 | BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016130774-A1 | BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-08-18 | — | — | WO | disclosed |
| US-20160152561-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2016-06-02 | — | — | US | disclosed |
| WO-2016016370-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-02-04 | — | — | WO | disclosed |
| US-8877970-B2 | Inhibitors of carbonic anhydrase IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | FLT3, CSF1R, CSF3R | MEN1 1656/4885KMT2A 1531/4885CA1 3188/4885 |
| US-10065937-B2 | FLT3 receptor antagonists | FLT3, CSF1R, CSF3R | MEN1 1656/4885KMT2A 1531/4885CA1 3188/4885 |
| US-10239830-B2 | Benzenesulfonamide upregulators of NPC1 for Neimann-Pick disease and other lysosomal storage disorders | GBA1, NPC1, NPC1L1 | MEN1 3616/4885KMT2A 1847/4885CA1 4821/4885 |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | CA9, CA12, CA1 | MEN1 1624/4885KMT2A 1452/4885CA1 3/4885 |
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | TRPV1, SCN1A, SCN5A | MEN1 3744/4885KMT2A 1684/4885CA1 598/4885 |
| US-20160152561-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN1A, SCN5A | MEN1 3744/4885KMT2A 1684/4885CA1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.